Scorpius Holdings Inc. · OTC:SCPX
Scorpius — NightHawk Biosciences — Investor Presentation (January 2024)
16 slides from Scorpius's investor presentation, Jan 16, 2024
Slide 1: NightHawk Biosciences Investor Presentation - January 2024
NightHawk Biosciences A rapidly growing, highly scalable biologics Contract Development & Manufacturing Organization (CDMO) Investor Presentation - January 2024 NYSE: NHWK
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, these forward - looking statements can be identified by the u se of forward - looking terminology, i
Slide 3: Full-Service CDMO Focused on Biologic Production for the Middle Market
Full - Service CDMO Focused on Biologic Production for the Middle Market Scorpius seeks to differentiate itself from competitors with a comprehensive mix of service offerings and a nimble, “boutique” approach to project planning and execution
Slide 4: Investment Highlights
Investment Highlights x Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical - scale manufacturing capacity within the industry x Pure - play biologics CDMO offering a comprehensive range of services from process and anal
Slide 5: Refocused and Recharged
Refocused and Recharged Recently divested non - core assets and contractual obligations to focus on Scorpius BioManufacturing operations » Terminated major in - house research activities » Divested non - core assets » Slashed non - core liabilities and burn rate These efforts have eliminated approxi
Slide 6: Increased Biologic Demand Driving Rapid Growth in CDMO Segment
Increased Biologic Demand Driving Rapid Growth in CDMO Segment Large Molecule Drug Substance CDMO Market size is poised to grow from $10.86B in 2022 to $21B by 2030, growing at a CAGR of 8.6% in the forecast period (2023 - 2030)* * SkyQuest Large Molecule Industry Forecast, July 2023 Over the last d
Slide 7: Business History
Business History Nov ’20: Scorpius BioManufacturing is founded Aug ’21: Broke ground on San Antonio, TX facility 2H ’22: Onboarded key execs and industry experts to build out management team Q4 ’22: Onboarded first client for microbial commercial contract Oct ’22: Opened San Antonio facility 2H ‘21
Slide 8: Scorpius Snapshot
Scorpius Snapshot Clinical - scale biomanufacturing in San Antonio, TX located in the heart of a thriving innovation district Highly skilled scientific and manufacturing leadership team US - sourced supply chain with US and international customers In - house process development and analytical servic
Slide 9: San Antonio Facility Overview
San Antonio Facility Overview Expertise in Mammalian and Microbial Manufacturing 40,000+ sq. ft. footprint includes – Brand new, state - of - the - art 40,000 sq. ft. facility with: • ~5,400 sq. ft. Mammalian / Cell Therapy manufacturing space • ~3,200 sq. ft. Microbial manufacturing space • ~2,000
Slide 10: Supported Drug Modalities
Supported Drug Modalities Phase - Appropriate Process Development Clinical - Scale Manufacturing Small - Scale Commercial Manufacturing Mammalian Cell Culture • Antibody Production • Monoclonals, Bi - Specifics • Recombinant Therapeutic Proteins • Allogeneic and Autologous Cell Therapy • Fc Fusions
Slide 11: Financial Profile: Robust Pipeline Supported by Streamlined Marketing Approach
Financial Profile Robust Pipeline Supported by Streamlined Marketing Approach » Since inception, Scorpius has signed 12+ development and manufacturing agreements , establishing strong brand recognition » Over $20M in signed contracts with substantial revenue from these contracts anticipated in 2024
Slide 12: Balance Sheet Highlights
Balance Sheet Highlights » Over $20 million of PP&E acquired without term debt (as of 09/30/23) » No term debt » ROU assets and liabilities represent all Scorpius facilities ($22M) and leased specialized equipment ($2.5M) (as of 09/30/23) » Capital investment into facility and equipment completed in
Slide 13: 2024 Goals
2024 Goals Plans to grow market share through several initiatives in 2024: » Deliver seamless execution on signed manufacturing contracts » Expand pipeline with target biotech, pharma, and research customers » Streamline operations to deliver at scale » Bolster and strengthen in - house development
Slide 14: Leadership Team
Leadership Team Joe Payne VP, Quality & Regulatory 20+ Years Of Experience Alcami , Tergus , Teva Brian O’Mara VP, Process Sciences 20+ Years Of Experience Ambrx , Bristol - Myers Squibb, Genencor, Wyeth Stephan Kutzer Senior Advisor 25+ Years Of Experience Alcami , Lonza Matt LeClair VP, Manufactur
Slide 15: Summary
Summary x Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical - scale manufacturing capacity within the industry x Scorpius began 2023 with $3M of signed manufacturing contracts, which has grown to over $20M in signed ma
Slide 16: A Full-Service CDMO Focused on Biologic Production for the Middle Market
A Full - Service CDMO Focused on Biologic Production for the Middle Market
NightHawk Biosciences — Investor Presentation (January 2024) on 6ix